Abivax’s Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer Show Good Tolerability and Promising Signals of Clinical Benefit and were Selected for Presentation at the ASCO GI Cancers Symposium 2022
ABX196 is Abivax's second compound in clinical development after lead drug-candidate ABX464ABX196 was well tolerated and demonstrated promising signals of...